(BAY 1129980/16044) An Open-Label Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
Primary objective: To determine the safety, tolerability and maximumtolerated dose (MTD) of BAY 1129980Secondary objective:To evaluate the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarkers, and tumor response profile of BAY 1129980.
Study Number: 

PH 253814

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.